Detalhe da pesquisa
1.
Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells.
Immunity
; 48(4): 760-772.e4, 2018 04 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29625893
2.
Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells.
Mol Ther
; 30(3): 1171-1187, 2022 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35051615
3.
Bifunctional TGF-ß trap/IL-15 protein complex elicits potent NK cell and CD8+ T cell immunity against solid tumors.
Mol Ther
; 29(10): 2949-2962, 2021 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34091051
4.
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.
Blood
; 131(23): 2515-2527, 2018 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29463563
5.
ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment.
J Virol
; 92(3)2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29118125
6.
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Lancet Oncol
; 19(5): 694-704, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29628312
7.
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.
PLoS Pathog
; 12(4): e1005545, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27082643
8.
Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
Cytokine
; 107: 105-112, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29452720
9.
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.
J Biol Chem
; 291(46): 23869-23881, 2016 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27650494
10.
Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
Int J Cancer
; 138(1): 187-94, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26174883
11.
In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice.
J Virol
; 89(12): 6264-74, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25833053
12.
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.
Science
; 383(6687): 1104-1111, 2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38422185
13.
Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretory phenotype in mice.
Aging Cell
; 22(5): e13806, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36967480
14.
A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy.
Cancer Immunol Res
; 9(9): 1071-1087, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34244297
15.
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells.
Cancer Res
; 78(11): 3067-3074, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29636345
16.
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery.
Nat Biotechnol
; 36(8): 707-716, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29985479
17.
The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles.
Blood Adv
; 2(2): 76-84, 2018 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365313
18.
New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.
Oncotarget
; 8(27): 44366-44378, 2017 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28574833
19.
Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control.
JCI Insight
; 2(23)2017 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29212951
20.
Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Oncotarget
; 7(1): 814-30, 2016 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26625316